Major Stakeholder Close To Blocking Adcock Sale To Chile's CFR
This article was originally published in PharmAsia News
Executive Summary
A large share purchase by one of Adcock Ingram's largest investors may be enough to block the still-pending $1.2 billion sale to CFR Pharmaceuticals.